VALTOCO Drug Patent Profile
✉ Email this page to a colleague
When do Valtoco patents expire, and what generic alternatives are available?
Valtoco is a drug marketed by Neurelis Inc and is included in one NDA. There are five patents protecting this drug.
This drug has ninety-five patent family members in twenty-eight countries.
The generic ingredient in VALTOCO is diazepam. There are eight drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the diazepam profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Valtoco
A generic version of VALTOCO was approved as diazepam by MYLAN on September 4th, 1985.
Summary for VALTOCO
International Patents: | 95 |
US Patents: | 5 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 63 |
Clinical Trials: | 2 |
Patent Applications: | 4,159 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for VALTOCO |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VALTOCO |
What excipients (inactive ingredients) are in VALTOCO? | VALTOCO excipients list |
DailyMed Link: | VALTOCO at DailyMed |


Recent Clinical Trials for VALTOCO
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Cincinnati | Phase 4 |
Neurelis, Inc. | Phase 1/Phase 2 |
Pharmacology for VALTOCO
Drug Class | Benzodiazepine |
Anatomical Therapeutic Chemical (ATC) Classes for VALTOCO
US Patents and Regulatory Information for VALTOCO
VALTOCO is protected by five US patents and two FDA Regulatory Exclusivities.
Patents protecting VALTOCO
Absorption enhancers for drug administration
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Administration of benzodiazepine compositions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Administration of benzodiazepine compositions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Absorption enhancers for intranasal administration
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: NASAL ADMINISTRATION OF DIAZEPAM FOR TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY IN PATIENTS 6 YEARS OF AGE AND OLDER
Pharmaceutical composition including alkyl glycoside and an anti-seizure agent
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
FDA Regulatory Exclusivity protecting VALTOCO
NEW PRODUCT
Exclusivity Expiration: ⤷ Try a Trial
INDICATED FOR THE ACUTE TX OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E. SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT’S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 6 YEARS OF AGE AND OLDER
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Neurelis Inc | VALTOCO | diazepam | SPRAY;NASAL | 211635-001 | Jan 10, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Neurelis Inc | VALTOCO | diazepam | SPRAY;NASAL | 211635-003 | Jan 10, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Neurelis Inc | VALTOCO | diazepam | SPRAY;NASAL | 211635-001 | Jan 10, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VALTOCO
See the table below for patents covering VALTOCO around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Spain | 2586032 | ⤷ Try a Trial | |
Denmark | 2720699 | ⤷ Try a Trial | |
Finland | 3415139 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |